LPOXY Therapeutics Secures $28M Financing to Combat C. difficile Infections LPOXY Therapeutics announces a $28 million Series A financing to support its groundbreaking STOP-Cdiff trial, targeting a major health threat.

LPOXY Therapeutics Secures $28M Financing to Combat C. difficile Infections #United_States #C._difficile #LPOXY_Therapeutics #Platte_City #STOP-Cdiff

LPOXY Therapeutics Enhances C. difficile Treatment with Acquisition of Xeno Assets LPOXY Therapeutics has acquired key assets from Xeno Biosciences to advance its C. difficile prevention therapy, SIDIPREV™, aiming for FDA approval in high-risk patients.

LPOXY Therapeutics Enhances C. difficile Treatment with Acquisition of Xeno Assets #USA #C._difficile #LPOXY_Therapeutics #Xeno_Biosciences #Platte_City